Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung CancerTony Mok, Vassiliki A. Papadimitrakopoulou, Yi‐Long Wu et al.|New England Journal of Medicine|2016Cited by 3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser H. Hanna, Paul A. Bunn, Frances A. Shepherd et al.|Journal of Clinical Oncology|2004Cited by 2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung CancerYi‐Long Wu, Roy S. Herbst, Masahiro Tsuboi et al.|New England Journal of Medicine|2020Cited by 1.7k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S. Kim, Jean‐Yves Douillard, Vera Hirsh et al.|The Lancet|2008Cited by 1.2k
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJoachim von Pawel, Richard J. Gralla, Joan H. Schiller et al.|Journal of Clinical Oncology|1999Cited by 960